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Research
Arsenic, cadmium, mercury, and lead are 
associated with cardiovascular disease in 
epidemiologic research (Engel et al. 1994; 
Houston 2007; Navas-Acien et al. 2007). 
These associations may be mediated by direct 
effects on blood pressure (BP) elevation. In 
animals, arsenic, cadmium, mercury, and lead 
induce hypertension (Navas-Acien et al. 2007; 
Satarug et al. 2006; Wakita 1987; Yang et al. 
2007), and manganese causes hypotension 
(Jiang and Zheng 2005). All five metals are 
plausibly linked with BP, based on mecha-
nistic and experimental data (Houston 2007; 
Jiang and Zheng 2005; Navas-Acien et al. 
2007; Valko et al. 2005).
Epidemiologic studies show consistent 
associations between high arsenic exposure 
and BP (Chen et al. 1995; Rahman et al. 
1999). Few studies have assessed lower-level 
exposure. Research on cadmium and BP is 
inconsistent (Staessen et al. 2000; Tellez-Plaza 
et al. 2008). Lead is a known risk factor for 
BP elevation (Navas-Acien et al. 2007), but 
no studies have evaluated toenail lead. High 
manganese exposure is associated with car-
diovascular dysfunction and hypotension in 
occupational cohorts (Jiang and Zheng 2005). 
Research at lower exposures is inconsistent 
(Gonzalez-Muñoz et al. 2010; Taneja and 
Mandal 2007). Studies examining mercury 
and BP report mixed results (Johansson et al. 
2002; Pedersen et al. 2005; Valera et al. 
2009). Data on low-level mercury are sparse.
We hypothesized that chronic arsenic, 
cadmium, mercury, and lead exposures elevate 
BP and that manganese lowers BP. We evalu-
ated these hypotheses in a cohort of elderly 
men from the Greater Boston area.
Materials and Methods
Study population. Subjects are from the 
on  going, longitudinal Veterans Administration 
Normative Aging Study (NAS) (Bell et al. 
1972). Participants are males with no known 
chronic medical conditions at recruitment. 
They are evaluated at study visits every 
3–5 years. This study has been approved by all 
relevant institutional review boards. All par-
ticipants gave their written informed consent.
We asked NAS participants to bring toe-
nail clippings to their study visit between 
January 1999 and January 2009 (n = 818 
eligible NAS participants). For our analy-
sis, we excluded NAS participants who did 
not bring toenail clippings (n = 165) or were 
missing information on BP (n = 3), race/eth-
nicity (n = 12), education (n = 22), alcohol 
intake (n = 11), age (n = 1), body mass index 
(BMI; n = 1), smoking history (n = 1), pack-
years (n = 1), or season of clinical visit (n = 1). 
Analyses included 639 men with toenail sam-
ples and complete information on BP and 
relevant covariates on at least one visit.
For each metal, we used data from first 
visits of the participants with complete infor-
mation on the specific metal of interest, BP, 
and relevant covariates in regressions against 
BP. In contrast, when reporting results for the 
study population as a whole (i.e., participant 
characteristics, toenail metal concentrations, 
and correlations between toenail metals), we 
used data from the first study visit of the par-
ticipants with donated toenails (even if some 
metal concentrations were missing) and com-
plete information on BP and covariates. Many 
NAS participants had more than one study 
visit between 1999 and 2009. Sometimes, 
data were missing on only certain metals at 
a given visit. Thus, the same participant may 
contribute data from different visits for, for 
example, arsenic–BP versus cadmium–BP 
regressions. Hence, sample sizes sometimes 
differ across metal–BP regressions even after 
adjustment for all other toenail metals.
Physical parameters and medical history. 
We asked participants to fast and abstain 
from smoking overnight prior to their morn-
ing visit. Height and weight were measured 
during physical examinations. Information 
on smoking and medications was obtained 
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Ba c k g r o u n d: Arsenic, cadmium, mercury, and lead are associated with cardiovascular disease in 
epidemiologic research. These associations may be mediated by direct effects of the metals on blood 
pressure (BP) elevation. Manganese is associated with cardiovascular dysfunction and hypotension 
in occupational cohorts.
oBjectives: We hypothesized that chronic arsenic, cadmium, mercury, and lead exposures elevate 
BP and that manganese lowers BP.
Me t h o d s : We conducted a cross-sectional analysis of associations between toenail metals and BP 
among older men from the Normative Aging Study (n = 639), using linear regression and adjusting 
for potential confounders.
re s u l t s: An interquartile range increase in toenail arsenic was associated with higher systolic BP 
[0.93 mmHg; 95% confidence interval (CI): 0.25, 1.62] and pulse pressure (0.76 mmHg; 95% CI: 
0.22, 1.30). Positive associations between arsenic and BP and negative associations between manga-
nese and BP were strengthened in models adjusted for other toenail metals.
co n c l u s i o n s: Our findings suggest associations between BP and arsenic and manganese. This may 
be of public health importance because of prevalence of both metal exposure and cardiovascular dis-
ease. Results should be interpreted cautiously given potential limitations of toenails as biomarkers 
of metal exposure.
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from questionnaires and confirmed by an on-
site physician. Alcohol and seafood intakes 
were determined using a standardized semi-
quantitative food frequency questionnaire 
(Willett et al. 1985).
Toenail samples. Toenails were collected 
from all toes, sonicated for 15 min in ~ 10 mL 
1% Triton X-100 solution, rinsed with dis-
tilled deionized water, dried at 60°C in a dry-
ing oven for 24 hr, and weighed. Mercury 
concentrations were measured by a different 
assay than the other metals. A sufficient quan-
tity of toenails was not always available for 
both assays. If weight was > 0.1 g, a portion 
of the sample was used for mercury analysis, 
and the rest was acid-digested and analyzed 
for multi-elements. Samples weighing < 0.1 g 
were not analyzed for mercury.
Among men otherwise eligible for inclu-
sion in metal–BP regressions, some were 
excluded because of cadmium concentrations 
below the detection limit (DL; n = 41) and/or 
samples of insufficient weight to assess metal 
concentrations (7 for cadmium, 72 for mer-
cury). One man had two otherwise eligible 
study visits during the period of toenail col-
lection but was excluded from cadmium–BP 
regressions because of cadmium concentra-
tion below the DL in one visit and insuffi-
cient sample weight in the other visit. No 
eligible participants were excluded because of 
metal concentrations below the DL for arse-
nic, mercury, manganese, or lead, or because 
of samples of insufficient weight for arsenic, 
manganese, or lead. We found no meaningful 
differences in characteristics between those 
with sufficient and insufficient sample weight 
for mercury assays (data not shown).
Arsenic, cadmium, manganese, lead. 
Samples were dissolved in HNO3 acid 
for 24 hr, diluted to 5 mL with deionized 
water, and analyzed by an inductively cou-
pled plasma-mass spectrometer (Elan 6100; 
PerkinElmer, Norwalk, CT, USA). Analyses 
were conducted through external calibration 
with thalium, indium, and tellurium as inter-
nal standards for lead, cadmium, and manga-
nese, and arsenic, respectively.
Quality control (QC) measures included 
analysis of the initial calibration verification 
standard (National Institute of Standard and 
Technology Standard Reference Material 
1643e, trace elements in water; Gaithersburg, 
MD, USA), a 1-ng/mL mixed-element standard 
solution, continuous calibration standards, and 
a procedural blank. Certified reference mate-
rial GBW 07601 was used as the QC sample; 
we used a large preparation (2 g/L) to monitor 
daily variation. Results were given as the average 
of five replicate measurements. Recovery of the 
analysis of the QC standard by this procedure 
was 90–110% with 95% precision.
The between-assay coefficient of variation 
was 3.6% for lead, 3.0% for cadmium, 3.3% 
for manganese, and 10% for arsenic. The DL 
for the analytical solution for all four met-
als was 0.2 × 10–3 µg/mL. The DL for the 
sample depends on sample weight. Sample 
weight varied from 0.002 g to 0.9 g, and 
the DL varied from 0.001 µg/g to 0.42 µg/g 
(mean = 0.02 µg/g).
Mercury. We conducted assays with the 
Direct Mercury Analyzer 80 (Milestone Inc., 
Monroe, CT, USA). Samples were analyzed 
using a matrix-matched calibration curve cre-
ated with different weights of certified ref-
erence material GBW 07601 (human hair; 
Institute of Geophysical and Geochemical 
Exploration, Langfang, Hebei Province, 
People’s Republic of China).
QC steps included daily calibration verifi-
cation of the high and low ends of the calibra-
tion curve, a procedural blank, and analysis of 
National Institute for Environmental Studies 
certified reference material 13 (human 
hair; Ibaraki, Japan). Mercury recovery was 
90–110%, with > 90% precision.
The DL for the mercury analysis was 
0.5 × 10–3 µg. The DL for the sample var-
ied according to sample weight. Sample 
weight varied from 0.01 g to 0.15 g, and 
the DL varied from 0.003 µg/g to 0.05 µg/g 
(mean = 0.018 µg/g).
BP measurements. Systolic BP (SBP) and 
fifth-phase diastolic BP (DBP) were measured 
by a physician at the same visit as toenail 
collection. BP readings were taken in each 
arm (to the nearest 2 mmHg) with standard 
mercury sphygmomanometers with 14-cm 
cuffs. The means of the arm measurements 
were used as the SBP and DBP of the par-
ticipants, and pulse pressure was calculated as 
SBP – DBP. BP was taken seated, immedi-
ately after a seated patient history.
Statistical methods. We examined cross-
sectional relations between toenail metals and 
BP from the same study visit using multi-
variable linear regression.
Antihypertensive medication use is a poten-
tial source of bias when examining associations 
with BP. People taking antihypertensives have 
controlled and likely artificially low BP. We 
address this by adding a constant (10 mmHg) 
to the SBP and DBP of participants using anti-
hypertensives (Cui et al. 2003; Tobin et al. 
2005). To test the robustness of our results, we 
ran a sensitivity analysis examining associations 
between toenail metals and BP without adding 
a constant to the SBP and DBP of antihyper-
tensive users. Results were similar when not 
correcting for medication use (data not shown).
We examined interactions with statins for 
metals associated with BP in any regression by 
adding interaction terms between metals and 
statin use (yes/no) to main effects models and 
by modeling stratified regressions.
The following potential confounders were 
identified from the literature and included in 
all models: age, cigarette smoking (never, cur-
rent, or former), pack-years, BMI (kilograms 
per square meter), alcohol intake (two or more 
vs. fewer than two drinks/day), race/ethnicity, 
education (years), and season and year of clini-
cal visit. For mercury, we adjusted for dark-
meat fish, shellfish, canned tuna, and other 
fish intake. To evaluate potential confounding 
by other toenail metals, we included all five 
metals together in the same regressions, retain-
ing all covariates.
To examine dose–response relationships 
between arsenic and BP, we refit regression 
models using the generalized additive model 
in R (R Project for Statistical Computing, 
Vienna, Austria). We fit a penalized spline and 
chose the optimum penalty using generalized 
cross validation.
We evaluated associations between an 
interquartile range (IQR) increase in toenail 
metals and hypertension (defined as antihyper-
tensive medication use or SBP ≥ 140 mmHg 
or DBP ≥ 90 mmHg at study visit) using 
logistic regression and adjusting for the afore-
mentioned confounders.
We conducted a sensitivity analysis using 
inverse probability weighting to adjust for 
potential selection bias (Hogan and Lancaster 
2004). We ran a logistic regression assessing 
relations between covariates and participation 
status, retaining variables that were significant 
at the p < 0.10 level (age, BMI, smoking). We 
obtained predicted probability of participa-
tion for each subject, and weighted regres-
sion models by inverses of these probabilities. 
Results were not appreciably altered by inverse 
probability weighting (data not shown).
Because a number of otherwise eligible 
participants were excluded from cadmium-BP 
regressions due to toenail concentrations 
below the DL, we also conducted a sensitiv-
ity analysis in which we assigned participants 
with cadmium concentrations below the DL a 
concentration value of the mean sample DL/2 
(0.01 µg/g).
Using Student’s t-test and chi-square 
analy  sis, we compared participants with non-
participants presenting during the same time 
period. For this comparison, we used data 
from the first NAS visit of the nonparticipants 
between January 1999 and January 2009 (the 
period of toenail collection). We also calcu-
lated medians and IQRs for toenail metal levels 
after stratifying by potential confounders and 
effect modifiers. Correlations between toenail 
metals were evaluated using Spearman correla-
tion. Regression results were similar, although 
somewhat weaker, when using log-transformed 
metal concentrations (data not shown).
Results
Study population. At their first study visit with 
donated toenails and complete information on 
BP and covariates, participants were mostly Mordukhovich et al.
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former smokers. Mean BMI was 28 kg/m2, 
and 20%, 53%, and 27% of participants had a 
BMI of < 25, 25–30, and ≥ 30 kg/m2, respec-
tively. Participants were younger than non-
participants (mean ages 72 and 74, respectively, 
p = 0.03) (Table 1). Mean uncorrected SBP 
and DBP were 133 mmHg and 78 mmHg, 
respectively, with 71% of participants classi-
fied as hypertensive based on medication use 
or BP at study visit. Sixty percent used anti-
hypertensives; 37% used statins.
Detailed information on metal concen-
trations by participant characteristics is 
provided in Supplemental Material, Table 1 
(http://dx.doi.org/10.1289/ehp.1002805). 
For example, arsenic was higher among 
men consuming two or more versus fewer 
than two alcoholic drinks per day (0.09 vs. 
0.07 µg/g); among non-Hispanic blacks 
compared with non-Hispanic whites (0.09 
vs. 0.08 µg/g), cadmium was higher among 
men consuming two or more versus fewer 
than two alcoholic drinks per day (0.02 vs. 
0.01 µg/g) and among men with fewer years 
of education (< 15 years vs. ≥ 15 years, 0.02 
vs. 0.01 µg/g); mercury was higher among 
men with greater dark-meat fish (0.31 vs. 
0.15 µg/g), other fish (0.26 vs. 0.15 µg/g), 
shellfish (0.27 vs. 0.18 µg/g), and tuna intake 
(0.25 vs. 0.12 µg/g) (one or more servings per 
month vs. less than one serving per month 
for each seafood category). Manganese was 
lower among statin users (0.24 vs. 0.31 µg/g) 
and was higher among non-Hispanic whites 
compared with non-Hispanic blacks (0.28 
vs. 0.18 µg/g); lead was higher among men 
consuming two or more versus fewer than two 
alcoholic drinks per day (0.38 vs. 0.30 µg/g) 
and among men with fewer years of education 
(< 15 years vs. ≥ 15 years, 0.35 vs. 0.26 µg/g). 
Toenail cadmium levels were similar across 
categories defined by smoking history or 
pack-years [Supplemental Material, Table 1 
(http://dx.doi.org/10.1289/ehp.1002805)], 
even when participants with cadmium con-
centrations below the DL were assigned a con-
centration value of 0.01 µg/g (mean sample 
DL/2; data not shown). Correlations between 
toenail metals are reported in Supplemental 
Material, Table 2 (http://dx.doi.org/10.1289/
ehp.1002805). Briefly, we found statistically 
significant correlations between arsenic and 
cadmium (r = 0.39), mercury (r = 0.09), man-
ganese (r = 0.56), and lead (r = 0.45), between 
cadmium and manganese (r = 0.49) and lead 
(r = 0.58), and between manganese and lead 
(r = 0.50) (Supplemental Material, Table 2).
Arsenic. An IQR (0.06 µg/g) increase 
in arsenic was associated with higher SBP 
[0.93 mmHg; 95% confidence interval (CI): 
0.25, 1.62] and pulse pressure (0.76 mmHg; 
95% CI: 0.22, 1.30) and showed a weak posi-
tive association with DBP (Table 2). Adjustment 
for other metals strengthened associations with 
SBP (1.43 mmHg, 95% CI: 0.34, 2.51) and 
DBP (0.63 mmHg, 95% CI: 0.05, 1.21). The 
association with pulse pressure was essentially 
unchanged but was less precise (Table 2).
We evaluated the dose–response relation-
ship between arsenic and SBP, using penal-
ized splines [Supplemental Material, Figure 1 
(http://dx.doi.org/10.1289/ehp.1002805)]. 
Out of a choice of up to 10 degrees of free-
dom, generalized cross validation chose a 





n = 179 p-Value
Age (years) 72 ± 6.6 74 ± 7.6 0.03
BMI (kg/m2) 0.38
< 25 130 ± 20 33 ± 19
25–29 338 ± 53 88 ± 49
≥ 30 171 ± 27 57 ± 32
Smoking status  0.17
Never smoker 186 (29) 43 (24)
Former smoker 430 (67) 124 (70)
Current smoker 23 (3.6) 11 (6.2)
Smoking (pack-years) 30 ± 28 31 ± 24 0.62
Years of education 15 ± 2.8 14 ± 2.9 0.96
Race/ethnicity 0.85
Non-Hispanic white 624 ± 98 162 ± 97
Non-Hispanic black 10 ± 1.6 4 ± 2.4
Hispanic white 4 ± 0.6 1 ± 0.6
Hispanic black 1 ± 0.2  0
Alcohol intake (drinks/day)
< 2 513 ± 80 138 ± 82 0.59
≥ 2 126 ± 20 30 ± 18
Year of clinical visit 2001 ± 2.1 2001 ± 2.4 0.28
Season of clinical visit 0.10
Spring 164 (26) 31 (17)
Summer 169 (26) 57 (32) 
Fall 187 (29) 59 (33)
Winter 119 (19) 31 (17)
Antihypertensive use 384 (60) 121 (68) 0.06
Statin use 235 (37) 64 (36) 0.84
BP (mmHg)
SBP 133 ± 17 133 ± 18 0.97
DBP 78 ± 9.3 77 ± 10 0.54
Pulse pressure 55 ± 14 56 ± 16 0.66
Data are given as mean ± SD or n (%). Participant data are from first study visit with donated toenails and complete 
information on BP and covariates. For comparison with eligible NAS subjects who were not included in the metal–BP 
analyses (i.e., nonparticipants), we used data from first NAS visit of nonparticipants between January 1999 and January 
2009 (the period of toenail collection).
Table 2. Linear regression models estimating the change in BP parameters associated with an IQR increase in metal levels.a,b
Change in BP (mmHg, 95% CI)
Toenail metal Median (μg/g) Range (μg/g) IQR (μg/g) n SBP DBP Pulse pressure
Arsenic 0.08 1.68 0.06 639 0.93 (0.25, 1.62)** 0.17 (–0.20, 0.55) 0.76 (0.22, 1.30)**
Arsenicc 466 1.43 (0.34, 2.51)* 0.63 (0.05, 1.21)* 0.80 (–0.07, 1.66)
Cadmium 0.02 1.97 0.02  592 0.22 (–0.10, 0.54) 0.12 (–0.05, 0.28) 0.11 (–0.15, 0.36)
Cadmiumc 495 0.21 (–0.13, 0.56) 0.08 (–0.10, 0.27) 0.13 (–0.15, 0.41)
Mercury 0.22 2.40 0.31 495 –0.56 (–2.27, 1.16) –0.21 (–1.16, 0.75) –0.35 (–1.70, 1.00)
Mercuryc 428 –0.76 (–2.68, 1.16) –0.27 (–1.32, 0.78) –0.49 (–2.00, 1.02)
Manganese 0.28  8.82 0.40 639 –0.45 (–1.18, 0.28) –0.12 (–0.51, 0.28) –0.33 (–0.91, 0.25)
Manganesec 465 –1.09 (–2.08, –0.10)* –0.62 (–1.15, –0.09)* –0.47 (–1.26, 0.32)
Lead 0.31 14.70 0.52 639 –0.07 (–0.67, 0.53) 0.24 (–0.08, 0.57) –0.31 (–0.78, 0.16)
Leadc 464 –0.22 (–0.93, 0.50) 0.27 (–0.11, 0.65) –0.49 (–1.06, 0.08)
aFor each metal, the same IQR value is examined in relation to BP for both metal-adjusted and non-metal-adjusted models. bAll regression models are adjusted for age, cigarette smok-
ing, pack-years of smoking, season of clinical visit, year of clinical visit, BMI, years of education, race/ethnicity, and alcohol intake. Mercury-BP models are adjusted for fish intake. cIn 
addition to the covariates in footnote b, this regression model is also adjusted for the four other toenail metals. *p < 0.05. **p < 0.01.Toenail metals and blood pressure
Environmental Health Perspectives  •  v o l u m e  120 | n u m b e r 1 | January 2012  101
slope of 1, indicating a linear association. 
Thus, there is no evidence of deviation from 
linearity in the arsenic–SBP model.
Cadmium. An IQR (0.02 µg/g) increase 
in cadmium was not significantly associated 
with BP (Table 2). Adjustment for other met-
als did not meaningfully alter these results 
(Table 2). Assigning participants with cad-
mium levels below the DL a concentration 
value of DL/2 did not appreciably alter results 
(data not shown).
Mercury. An IQR (0.31 µg/g) increase in 
mercury was negatively but not significantly 
associated with BP (SBP: –0.56, 95% CI: 
–2.27, 1.16; DBP: –0.21 mmHg, 95% CI: 
–1.16, 0.75; pulse pressure: –0.35 mmHg, 
95% CI: –1.70, 1.00) (Table 2). Adjustment 
for other metals did not meaningfully affect 
these results (Table 2). Mercury regressions 
have a considerably smaller sample size than 
regressions for other metals (Table 2) because 
of toenail samples of insufficient weight 
to assess mercury concentrations as well as 
adjustment for fish and shellfish intake.
Manganese. Manganese was negatively 
but not significantly associated with BP (SBP: 
–0.45 mmHg, 95% CI: –1.18, 0.28; DBP: 
–0.12 mmHg, 95% CI: –0.51, 0.28; pulse 
pressure: –0.33 mmHg, 95% CI: –0.91, 0.25) 
(Table 2). After adjusting for other metals, an 
IQR (0.40 µg/g) increase in manganese was 
more strongly associated with decreased SBP 
(–1.09 mmHg; 95% CI: –2.08, –0.10) and 
DBP (–0.62 mmHg; 95% CI: –1.15, –0.09).
Lead. An IQR (0.52 µg/g) increase 
in lead was not associated with BP (SBP: 
–0.07 mmHg, 95% CI: –0.67, 0.53; DBP: 
0.24 mmHg, 95% CI: –0.08, 0.57; pulse 
pressure: –0.31 mmHg, 95% CI: –0.78, 0.16) 
(Table 2). Adjustment for other metals did 
not meaningfully alter these results (Table 2).
Hypertension. Estimated associations of 
hypertension with an IQR increase in toenail 
metals were consistent with linear regression 
results [arsenic, odds ratio (OR) = 1.07, 95% 
CI: 0.97, 1.20; cadmium, OR = 1.01, 95% 
CI: 0.95, 1.06; mercury, OR = 0.85, 95% CI: 
0.68, 1.05; manganese, OR = 0.96, 95% CI: 
0.87, 1.05; lead, OR = 1.00, 95% CI: 0.92, 
1.08]. Upon adjusting for other metals, man-
ganese was negatively associated with hyper-
tension (OR = 0.88; 95% CI: 0.77, 0.999). 
Similar adjustment did not meaningfully alter 
the other results (data not shown).
Effect modification. We found a significant 
interaction between arsenic and statins for DBP 
but not for SBP or pulse pressure (Table 3). 
Among men not taking statins (n = 404), an 
IQR increase in arsenic was associated with an 
increase in DBP (0.76 mmHg; 95% CI: 0.20, 
1.33). Arsenic showed a non  significant nega-
tive association with DBP among statin users 
(n = 235; –0.30 mmHg; 95% CI: –0.80, 0.21). 
Within the sample included in arsenic–BP 
analyses, statin and antihypertensive use were 
strongly associated with each other based on 
chi-square analysis and age-adjusted logistic 
regression (data not shown).
We found no significant interactions 
between manganese and statins (SBP: p = 0.76, 
DBP: p = 0.39; pulse pressure: p = 0.84). 
Results were similar after adjustment for other 
metals (data not shown).
Discussion
In a cohort of elderly men with low toenail 
arsenic concentrations, we found positive 
associations between toenail arsenic and BP 
levels. Our results also tentatively suggest neg-
ative associations between toenail manganese 
and BP levels. We found little evidence of 
associations with toenail cadmium, mercury, 
or lead. If confirmed, these results may be 
important because of the high prevalence of 
both cardiovascular disease and low to moder-
ate metal exposures in the United States.
No investigations have assessed relations 
between arsenic, cadmium, mercury, man-
ganese, or lead and BP using toenails as bio-
markers. Toenail samples are convenient to 
collect and store, grow more slowly than hair, 
are more protected from external contami-
nants, and represent longer-term exposures 
than blood or urine (Slotnick and Nriagu 
2006). Toenails likely reflect metal exposures 
from the preceding 12–18 months, with 
slower growth among the elderly (Slotnick 
and Nriagu 2006).
Arsenic. Arsenic may elevate BP through 
pathways related to oxidative stress (Valko 
et al. 2005), inflammation (Wu et al. 2003), 
and endothelial dysfunction/nitric oxide inhi-
bition (Pi et al. 2000).
Epidemiologic studies have mostly evalu-
ated inorganic arsenic, which is more toxic 
than organic arsenic. Our toenail assay does 
not distinguish between forms. However, sea-
food is the main source of organic arsenic 
(Slotnick and Nriagu 2006). Toenail arsenic 
is very weakly or not at all correlated with fish 
(dark-meat fish: r = 0.06; other fish: r = 0.09; 
tuna: r = -0.004) and shellfish (r = 0.06) 
intake among our participants.
Arsenic sources include soil, dust, air, 
and food (Benbrahim-Tallaa and Waalkes 
2008; Slotnick and Nriagu 2006). Water 
is a potentially important inorganic arse-
nic source (Slotnick and Nriagu 2006). The 
Massachusetts Water Resources Authority 
(MWRA), in which arsenic is consistently 
undetectable (< 1.0 µg/L) (MWRA 2011), 
supplies most of the Greater Boston area.
Arsenic is found in toenails because of its 
high affinity to sulfhydryl groups (Karagas 
et al. 2000). Toenails are validated biomark-
ers of arsenic exposure (Slotnick et al. 2007; 
Slotnick and Nriagu 2006). Toenail con-
centrations in our study appear similar to 
those reported in most U.S. general popula-
tion studies (Garland et al. 1993; Karagas 
et al. 2001; Kwong et al. 2010; Slotnick et al. 
2005, 2007; Tsuji et al. 2005). Other U.S. 
studies report somewhat higher (Adair et al. 
2006; MacIntosh et al. 1997) or lower (Beane 
Freeman et al. 2004) arsenic levels.
Several investigations have assessed rela-
tions between high-level arsenic exposure and 
BP. These include two population-based anal-
yses that found dose–response relationships 
between well-water arsenic and hyperten-
sion (Chen et al. 1995; Rahman et al. 1999). 
Exposure categories used in these studies 
(10–700, 710–900, > 900 µg/L, and < 500, 
500–1,000, > 1,000 µg/L, respectively) are 
much greater than the maximum contami-
nant level for arsenic in the United States 
(10 µg/L), although in practice this target 
value is often exceeded in U.S. drinking water 
sources [Agency for Toxic Substances and 
Disease Registry (ATSDR) 2007]. A recent 
Iranian study also found positive associations 
between high-level arsenic exposure and BP 
(Dastgiri et al. 2010).
Two  population-based  studies  in 
Bangladesh and Inner Mongolia (with expo-
sure categories of < 8, 8.1–40.8, 40.9–91.0, 
91.1–176.0, 176.1–864.0 µg/L, and < 20, 
21–50, 51–100, > 100 µg/L drinking water, 
respectively) reported positive associations 
between more moderate arsenic levels and 
BP-related outcomes (Chen et al. 2007; Kwok 
et al. 2007). A U.S. study found an association 
between well-water arsenic levels of ≥ 10 µg/L 
versus < 2 µg/L and self-reported high BP 
(Zierold et al. 2004).
We found positive associations between 
arsenic and BP levels, consistent with the cur-
rent literature. Our study likely evaluated con-
siderably lower arsenic exposure levels than 
previous investigations, because arsenic is con-
sistently undetectable in the main water supply 
for the Greater Boston area (MWRA 2011). 
Table 3. Effect modification of the association between an IQR increase in toenail arsenic levela and BP 
by statin use (n = 639).b
Change in BP (mmHg) (95% CI)
Current statin use SBP DBP  Pulse pressure
No (n = 404) 1.46 (0.45, 2.47)** 0.76 (0.20, 1.33)** 0.69 (–0.08, 1.46)
Yes (n = 235) 0.64 (–0.32, 1.61) –0.30 (–0.80, 0.21) 0.94 (0.15, 1.74)*
p-Value for interaction 0.23 0.01 0.81
aIQR for arsenic: 0.06 μg/g. bRegression models were adjusted for age, cigarette smoking, pack-years of smoking, sea-
son of clinical visit, year of clinical visit, BMI, years of education, race/ethnicity, and alcohol intake. *p < 0.05. **p < 0.01.Mordukhovich et al.
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Our study was the first to use a biomarker of 
arsenic dose when assessing relations with BP.
Cadmium. Cadmium may act on BP 
through mechanisms related to oxidative stress 
(Valko et al. 2005), inflammation (Kayama 
et al. 1995), endothelial dysfunction, par-
tial agonism of calcium channels, increased 
vasoconstriction, and activation of the sym-
pathetic nervous system (Varoni et al. 2003). 
It may also act through renal tubular dam-
age, sodium retention, and volume overload 
(Satarug et al. 2006).
Food from cadmium-contaminated soils is 
a major exposure source (Satarug and Moore 
2004). Other sources include tobacco smoke, 
soil, dust, water, and air pollution (Henson 
and Chedrese 2004; Satarug and Moore 2004).
Toenail cadmium concentrations were 
lower in our study than in other U.S. general 
population studies (Platz et al. 2002; Slotnick 
et al. 2005; Yoshizawa et al. 2002). Data on 
validity of toenails as cadmium biomarkers 
are sparse. Most relevant studies found asso-
ciations between cadmium exposure and con-
centrations in toenails or nails (Anwar 2005; 
Mortada et al. 2002; Vinceti et al. 2007). 
However, toenail levels did not vary with 
smoking (a major cadmium source) among 
our participants. This may reflect shortcom-
ings of toenails as cadmium biomarkers or 
other factors, such as the potential influence 
of non  tobacco cadmium sources. In addition, 
few participants were active smokers, and 
number of pack-years likely reflects an expo-
sure window too distant to influence current 
toenail concentrations.
The literature regarding cadmium and BP 
is inconsistent. Investigations report positive 
(Satarug et al. 2005; Tellez-Plaza et al. 2008) 
and null (Staessen et al. 1991, 2000) associa-
tions with BP. One ecologic analysis reported 
a negative relation (Kagamimori et al. 1986). 
We found little evidence of associations 
between cadmium and BP. This should be 
interpreted cautiously in light of an unvali-
dated biomarker of exposure.
Mercury. Mercury may act on BP through 
mechanisms related to oxidative stress, vascu-
lar inflammation, endothelial dysfunction/
nitric oxide inhibition, renal tubular dysfunc-
tion, and proteinuria (Houston 2007).
Mercury exposure occurs primarily through 
seafood and dental amalgams (Brodkin et al. 
2007). Toenail mercury is a reliable, well-
  validated biologic marker of long-term expo-
sure to the metal (Garland et al. 1993; Joshi 
et al. 2003; MacIntosh et al. 1997; Rees et al. 
2007). Toenail mercury concentration in our 
analysis was similar to other general population 
studies (Garland et al. 1993; Rees et al. 2007) 
but lower than in the U.S. Health Professionals 
Follow-Up Study (Joshi et al. 2003).
The overall evidence on mercury and BP 
is inconsistent, with studies reporting positive 
and null associations (Johansson et al. 2002; 
Pedersen et al. 2005; Valera et al. 2009). Data 
on associations between low-level mercury 
and BP are sparse. We found little evidence of 
an association between mercury and BP.
Manganese. Manganese may act on BP by 
lowering vascular sensitivity to alpha-  adrenergic 
receptor activation, decreasing dopamine levels, 
and inducing oxidative stress. It may also act 
through antagonism of the alpha-  adrenergic 
receptor in blood vessels, calcium channel 
antagonism, or effects on the autonomic ner-
vous system (Jiang and Zheng 2005).
Manganese exposure occurs through 
food, water, air, and soil (Santamaria 2008). 
Manganese is associated with hypotension 
and decreased BP in animal (Jiang and Zheng 
2005) and occupational research (Jiang et al. 
2002; Su et al. 1998). Postural hypotension 
was observed in manganese dipyridoxyldiphos-
phate overdosed patients (Misselwitz et al. 
1995). Toenail manganese concentration in 
our investigation is similar, although slightly 
lower, relative to another U.S. general popula-
tion study (Slotnick et al. 2005).
Environmental manganese is gener-
ally considered to lower hypertension risk 
(Houtman 1996). However, non  occupational 
studies have reported positive (Taneja and 
Mandal 2007), null (Tubek and Tubek 2008), 
and negative (Gonzalez-Muñoz et al. 2010) 
associations with BP-related outcomes. Results 
may differ across investigations because of 
variations in study design, confounder control, 
metal measurement, definition or measure-
ment of the BP outcome, manganese exposure 
level, and participant characteristics.
We found negative relations between toe-
nail manganese and BP in models adjusted 
for other metals. This is consistent with results 
observed in occupational investigations. 
However, these tentative results should be 
interpreted extremely cautiously, because toe-
nails are not validated biomarkers of environ-
mental manganese exposure.
Lead. Proposed mechanisms linking lead 
to BP elevation include effects on kidney func-
tion, oxidative stress, and nitric oxide and 
guanylate cyclase levels, and changes in the 
renin-  angiotensin system (Navas-Acien et al. 
2007).
Lead is associated with hypertension and 
BP elevation in occupational and experimen-
tal animal research and in many environmen-
tal epidemiologic studies (Navas-Acien et al. 
2007). A recent systematic review concluded 
that this association is causal (Navas-Acien et al. 
2007). Bone lead, which represents cumula-
tive lead exposure (Hu et al. 2007), is consis-
tently associated with BP outcomes in the NAS 
(Cheng et al. 2001; Hu et al. 1996; Perlstein 
et al. 2007). Toenail lead levels in our analysis 
were similar to those of adults in another U.S. 
general population study (Slotnick et al. 2005).
Exposure occurs primarily through inhala-
tion of lead dust and ingestion of contami-
nated food and water (Rosin 2009). Toenails 
are not validated biomarkers of lead exposure. 
In fact, some research suggests that nails may 
be inappropriate biomarkers for lead (Barbosa 
et al. 2005). We found no association between 
toenail lead and BP, perhaps because of a 
number of factors. For example, toenail lead 
represents a shorter averaging time than bone 
lead. Alternatively, toenails may be a poor lead 
biomarker. Among men included in lead–BP 
analyses, toenail lead was weakly correlated 
with blood lead (r = 0.28, p < 0.0001), but not 
tibia (r = 0.04, p = 0.55) or patella (r = 0.03, 
p = 0.64) lead (blood and bone lead were 
measured as described by Hu et al. 1996).
Effect modification. Statins reduce inflam-
mation and oxidative stress, including in the 
vascular endothelium, and increase nitric 
oxide levels (Rubba 2007).
We found statistically significant inter-
action between arsenic and statins for DBP, 
with associations limited to statin non  users. 
Thus, it is possible that statins blunt effects 
of arsenic on DBP, although this interaction 
needs to be evaluated in other studies. We 
found no evidence of interactions between 
manganese and statin use.
Study Limitations and Future 
Research Directions
The cross-sectional design of our investiga-
tion precludes us from ascertaining causality. 
We had limited power to assess interactions. 
In addition, our study population consists 
almost entirely of white, elderly men.
Another limitation is using toenails as bio-
markers. Although toenails are validated bio-
markers for mercury and arsenic, their validity 
is unclear for cadmium and manganese and 
has been called into question for lead. It is very 
important to interpret results with caution. BP 
readings are based on only one study visit, 
although BP is variable and affected by many 
stimuli. This variability may attenuate results.
We did not correct for multiple com-
parisons. We have examined five metals. 
However, they all have pathway-based sup-
port for associations with BP, and we believe 
that our study should not be penalized relative 
to investigations examining only individual 
metals under these circumstances.
More research is needed to address rela-
tions between metals and BP among larger, 
more diverse prospective cohorts. Potential 
interactions between arsenic and statins should 
be evaluated in future analyses.
Conclusions
Our findings suggest that environmental arse-
nic may be associated with BP. Our analyses 
also tentatively suggest that toenail manga-
nese may be associated with decreased BP. We Toenail metals and blood pressure
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found no consistent associations with IQR 
increases in toenail mercury, cadmium, or 
lead. These findings should be interpreted in 
light of the difficulty of ascertaining fish intake 
[the beneficial cardiovascular effects of this 
important mercury source (Appel et al. 1993) 
may confound associations between toenail 
mercury and BP] and potential shortcomings 
of toenails as biomarkers for metal exposure.
Although changes in BP reported here are 
not clinically relevant on an individual level, 
shifting the population distribution of BP has 
public health significance (Dickinson et al. 
2007). Findings of associations for arsenic at 
these levels, if confirmed, suggests that cur-
rent efforts to regulate arsenic exposure in the 
general population may be inadequate.
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